Eli Lilly Slips as Healthcare Stocks Face Consumer Spending Headwinds

Eli Lilly, a dominant force in the weight-loss drug market, surrendered a portion of its recent gains. Despite the decline, the stock continues to trade near all-time highs as the pharmaceutical giant maintains its momentum in the obesity treatment space.

In a separate development, Ruthia He, founder and former chief executive of the telehealth startup Done Global, received a six-year prison sentence. Federal prosecutors had successfully argued that the platform functioned as a digital pill mill, facilitating the illicit distribution of Adderall.